2025-09-14 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the data you provided. I'll present the key figures first, followed by a more detailed analysis.

## TG Therapeutics (TGTX) Analysis

**Ticker:** TGTX
**Company:** TG Therapeutics Inc. (A biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.)

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 74.39%
*   **VOO Cumulative Return:** 89.18%
*   **Absolute Divergence:** -121.4
*   **Relative Divergence:** 17.1

**Analysis:** TGTX has underperformed the S&P 500 over the period examined. The relative divergence suggests that TGTX's performance is in the lower range of its historical divergence from the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -2.0%   | 2.0%  | -4.0%   | -1.4   | 1.3    |
| 2016-2018  | -54.0%  | 58.7% | -50.0%  | -0.0   | 0.7    |
| 2017-2019  | 32.0%   | 58.7% | 10.0%   | -0.0   | 1.8    |
| 2018-2020  | 424.0%  | 58.7% | 397.0%  | -0.0   | 8.2    |
| 2019-2021  | 132.0%  | 63.5% | 83.0%   | -0.0   | 3.0    |
| 2020-2022  | -84.0%  | 70.4% | -91.0%  | 0.0    | 1.9    |
| 2021-2023  | -380.0% | 70.4% | -400.0% | -0.7   | 2.7    |
| 2022-2024  | 72.0%   | 73.1% | 45.0%   | -0.8   | 4.8    |
| 2023-2025  | 76.0%   | 73.1% | 22.0%   | -0.0   | 5.1    |

**Analysis:**
*   **CAGR:** Wide swings in annual growth, from significant losses to substantial gains.  Recent years show positive growth.
*   **MDD:** Consistently high Maximum Drawdown indicates significant volatility and risk.
*   **Alpha:**  Varies considerably, showing periods of significant outperformance and underperformance relative to the market.
*   **Beta:** Generally low (close to zero or negative), suggesting the stock has not moved in lockstep with the broader market and may be less sensitive to market movements.
*   **Cap(B):** Market Cap changes over time.

### 2. Recent Price Action

*   **Current Price:** 32.16
*   **Previous Close:** 32.46
*   **Change:** -0.92%
*   **5-Day Moving Average:** 32.165
*   **20-Day Moving Average:** 30.0972
*   **60-Day Moving Average:** 33.2151

**Analysis:** The price has decreased slightly. The price is currently slightly below the 5-day moving average, above the 20-day moving average, and below the 60-day moving average. This mixed signal suggests potential short-term consolidation or slight downward pressure.

### 3. Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 70.0962 (Approaching overbought territory)
*   **PPO:** 1.6701
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** -0.3 (Short-term decline)
*   **Expected Return:** -565.3% (Significant underperformance vs. S&P 500)

**Analysis:** The MRI suggests low market risk. The RSI nearing 70 indicates that the stock may be overbought in the short term. The negative change in relative divergence over the past 20 days suggests recent underperformance. The "Hybrid Signal" recommends caution, with a small buy allocation.  The extremely negative expected return is a major concern.

### 4. Recent News & Events

*   **Insider Selling:** A recent insider sale of shares worth $672,268 could be a negative signal, but requires further context.
*   **BRIUMVI Data Presentations:** Upcoming data presentations on BRIUMVI for multiple sclerosis are a positive catalyst.
*   **Phase 3 Trial Enrollment:** Commencement of a Phase 3 trial for subcutaneous BRIUMVI is also a positive development.
*   **Buyback Program:**  A $100 million buyback program is intended to boost investor confidence and potentially increase the stock price.
*   **Participation in Investment Conference:** Participation in the H.C. Wainwright conference suggests efforts to engage with investors.
*   **CEO Confidence:** The CEO's strong conviction in Briumvi and the buyback indicate confidence in the company's prospects.

**Analysis:** The news is a mix of positive and potentially negative. The insider selling is a caution, while the clinical trial updates, conference participation, and buyback program are generally positive.

### 4-2. Analyst Opinions

*   **Consensus:** Neutral
*   **Opinions:** 6
*   **Target Price (avg/high/low):** 40.50 / 53.00 / 11.00

**Analysis:** Analyst opinions are neutral with a wide range of target prices. The average target price suggests some upside potential.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2024-08-09 | 0.05 | 0.07 B$    |
| 2025-08-08 | 0.05 | 0.07 B$    |

**Analysis:** Recent EPS and revenue figures show improvement in the most recent quarter. There appears to be a duplicate entry for 2025-08-08.

### 6. Financial Information

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |
| 2024-06-30   | $0.07B  | 88.70%        |

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-06-30   | $0.28B  | 10.20%    |
| 2025-03-31   | $0.24B  | 2.13%     |
| 2024-12-31   | $0.22B  | 10.49%    |
| 2024-09-30   | $0.19B  | 2.02%     |
| 2024-06-30   | $0.18B  | 3.87%     |

**Analysis:** Revenue is trending upward, and profit margins are very high. Equity is increasing, and ROE fluctuates but shows recent improvement.

### 7. 종합적인 분석 (Overall Analysis)

**Summary:**

TG Therapeutics (TGTX) presents a mixed picture. While the company is showing positive momentum in revenue, profit margins, and recent earnings, there are also concerning factors:

*   **Underperformance:** Significant historical underperformance compared to the S&P 500.
*   **High Volatility:**  The high MDD and fluctuating Alpha/Beta demonstrate substantial volatility.
*   **Negative Expected Return:** The extremely negative expected return is a significant red flag.
*   **Mixed Signals:** Technical indicators provide mixed signals, with the RSI suggesting overbought conditions and a recent short-term decline.
*   **News:**  The news flow is mixed, with positive developments in clinical trials and a buyback program offset by insider selling.
*   **Analyst Consensus:** Neutral analyst opinions with a wide range of price targets suggest uncertainty about the stock's future.

**Conclusion:**

Based on this analysis, TG Therapeutics appears to be a **high-risk, potentially high-reward investment**. While the company is making progress, the historical underperformance, volatility, and negative expected return warrant caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in TGTX. The positive catalysts (clinical trial progress, buyback) need to be weighed against the potential negatives (insider selling, historical performance).
